Minecoside

Minecoside

SCHEMBL29426074

COc1ccc(/C=C/C(=O)O[C@H]2[C@@H]3C=CO[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]3[C@@]3(CO)O[C@@H]23)cc1O

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 8/20 0.85
▸ XDH P47989 1/20 0.61
▸ SNCA P37840 1/20 0.46
▸ CYP3A4 P08684 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GLA P06280 1/20 0.45
▸ PRKCA P17252 3/20 0.44
▸ LDHA P00338 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ KDM1A O60341 1/20 0.43
▸ BACE1 P56817 1/20 0.43
▸ PTPN1 P18031 1/20 0.43
▸ EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29642990 0.94 HSP90AA1 (0.85) HSP90AA1XDHSNCACYP3A4KDM4E
Verminoside SCHEMBL29425838 0.92 HSP90AA1 (1.00) HSP90AA1XDHCYP3A4KDM4EGLA
SCHEMBL29642977 0.89 HSP90AA1 (0.71) HSP90AA1XDHSNCACYP3A4KDM4E
Specioside SCHEMBL29426185 0.88 HSP90AA1 (1.00) HSP90AA1XDHCYP3A4KDM4EGLA
SCHEMBL423457 0.88 HSP90AA1 (0.74) HSP90AA1XDHSNCACYP3A4PRKCA
SCHEMBL422039 0.86 HSP90AA1 (0.71) HSP90AA1XDHSNCACYP3A4KDM4E
SCHEMBL29546041 0.84 HSP90AA1 (0.76) HSP90AA1XDHCYP3A4KDM4EGLA
SCHEMBL29425876 0.82 HSP90AA1 (0.84) HSP90AA1XDHCYP3A4KDM4EGLA
Picroside Ii SCHEMBL24209282 0.82 HSP90AA1 (0.78) HSP90AA1XDHKDM4EL3MBTL1
Picroside Ii SCHEMBL24209283 0.82 HSP90AA1 (0.78) HSP90AA1XDHKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029273-A Compositions and methods for activating immune cells MDX管理有限责任公司 2026-05-12 — — CN disclosed
EP-4702037-A1 METHOD OF PRODUCING IRIDOIDS Nicoventures Trading Limited (GB) 2026-03-04 — — EP disclosed
US-20250205337-A1 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX MAN LLC (US) 2025-06-26 — — US disclosed
CN-119562818-A Compositions and methods for activating immune cells MDX管理有限责任公司 2025-03-04 — — CN disclosed
WO-2025038745-A1 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX MANAGEMENT LLC (US) 2025-02-20 — — WO disclosed
EP-4499117-A1 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX Management LLC (US) 2025-02-05 — — EP disclosed
WO-2024224085-A1 METHOD OF PRODUCING IRIDOIDS Nicoventures Trading Limited (GB) 2024-10-31 — — WO disclosed
WO-2023192542-A9 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX MANAGEMENT LLC (US) 2024-08-15 — — WO disclosed
WO-2023192542-A1 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX MANAGEMENT LLC (US) 2023-10-05 — — WO disclosed
EP-3409766-B1 AN ESTERASE THAT IS CAPABLE OF CONVERTING IRIDOIDS AND SECO-IRIDOIDS N ZYME BIOTEC GMBH (DE) 2022-03-09 — — EP disclosed
Send feedback